Mikronährstoffe in den verschiedenen Lebensphasen der Frau (Teil 4) - Schwangerschaft: Vitamin D, Jod und Co.

Alexander Ströhle, Maike Wolters, Peyman Hadji, Andreas Hahn

 

  1. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O'Beirne M, Rabi DM. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. BMJ. 2013;346:f1169. 
  2. Alzaim M, Wood RJ. Vitamin D and gestational diabetes mellitus. Nutr Rev. 2013;71:158-67. 
  3. Arbeitskreis Jodmangel. Jodversorgung bei Schwangeren und Stillenden. Online verfügbar unter: jodmangel.de/ausreichende-jodversorgung/schwangere-und- stillende/#empfehlungen%20des%20akj
  4. Bath SC, Steer CD, Golding J, Emmett P, Rayman MP. Effect of inadequate iodine status in UK pregnant women on cognitive outcomes in their children: results from the Avon Longitudinal Study of Parents and Children (ALSPAC). Lancet. 2013;382:331-7. 
  5. Becker DV, Braverman LE, Delange F, et al. Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association. Thyroid 2006;16:949–51.
  6. Bischoff-Ferrari HA. Relevance of vitamin D in muscle health. Rev Endocr Metab Disord. 2012;13:71-7.
  7. Bohnet HG. Jodmangel und Jodversorgung in der Schwangerschaft und Stillzeit. Maßahmen, Prophylaxeerfolge und Probleme. Präv Gesundheitsf. 2007;2:175-178
  8. Bozzetto S, Carraro S, Giordano G, Boner A, Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy. 2012;67:10-7.
  9. Chang K, Shin JI. Association of gestational maternal hypothyroxinemia and increased autism risk: The role of BDNF ? Ann Neurol. 2014 Mar 19. doi: 10.1002/ana.24143. [Epub ahead of print] PubMed PMID: 24752853.
  10. Clancy N, Onwuneme C, Carroll A, McCarthy R, McKenna MJ, Murphy N, Molloy EJ. Vitamin D and neonatal immune function. J Matern Fetal Neonatal Med. 2013;26:639-46. 
  11. Deutsche Gesellschaft für Ernährung e.V. (DGE), Österreichische Gesellschaft für Ernährung (ÖGE), Schweizerische Gesellschaft für Ernährungsforschung (SGE), Schweizerische Vereinigung für Ernährung (SVE). Referenzwerte für die Nährstoffzufuhr. 1. Auflage, 5., korrigierter Nachdruck, Umschau, Braus; Frankfurt; 2013
  12. EFSA. Opinion of the scientific committee on food on the tolerable upper intake level of iodine; 2002. Online verfügbar unter ec.europa.eu/food/fs/sc/scf/out146_en.pdf.
  13. EFSA. Scientific opinion on the tolerable upper intake level of vitamin D. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal 2012;10:2813. Online verfügbar unter: www.efsa.europa.eu/de/efsajournal/doc/2813.pdf
  14. Eidgenössisches Departement des Innern (EDI), Bundesamt für Gesundheit (BAG), Direktionsbereich Verbraucherschutz: Vitamin-D-Empfehlungen des Bundesamtes für Gesundheit BAG, Juni 2012 (online verfügbar unter www.bag.admin.ch/themen/ernaehrung_bewegung/05207/13246/index.html)
  15. Evans KN, Bulmer JN, Kilby MD, Hewison M. Vitamin D and placental-decidual function. J Soc Gynecol Investig. 2004;11:263-71.
  16. Gärtner R, Reincke M. Schilddrüse. In: Siegenthaler Wm Blum HE (Hrsg.). Klinische Pathophysiologie. 9. Auflage, Stuttgart, Thieme; 2006, S. 270-290
  17. Gärtner R. [Thyroid disorders during pregnancy]. Dtsch Med Wochenschr. 2009;134:83-6.
  18. Ghassabian A, El Marroun H, Peeters R, Jaddoe VW, Hofman A, Verhulst FC, Tiemeier H, White T. Downstream effects of maternal hypothyroxinemia in early pregnancy: Nonverbal IQ and brain morphology in school age children. J Clin Endocrinol Metab. 2014 Mar 31:jc20134281. [Epub ahead of print] PubMed PMID: 24684462.
  19. Godel JC, Canadian Paediatric Society, First Nations, Inuit and Métis Health Committee. Vitamin D supplementation: Recommendations for Canadian mothers and infants. Paediatr Child Health 2007;12:583-9. Online verfügbar unter: www.cps.ca/documents/position/vitamin-d
  20. Grüters A, Biebermann H, Krude H. Neonatal thyroid disorders. Horm Res. 2003;59 Suppl 1:24-9.
  21. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549-55.
  22. Hahn A, Ströhle A, Wolters M. Ernährung. Physiologische Grundlagen, Prävention, Therapie. Stuttgart, Wissenschaftliche Verlagsgesellschaft; 2014 (im Druck)
  23. Hampel R, Bennöhr G, Gordalla A, Below H. Urinary iodide excretion in adults in germany 2005 meets WHO target. Exp Clin Endocrinol Diabetes. 2010;118:254-7.
  24. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-30.
  25. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am. 2010;39:381-400. 
  26. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011;26:2341-57. 
  27. Hollis BW, Wagner CL. Assessment of dietary vitamin D requirements during pregnancy and lactation. Am J Clin Nutr. 2004;79:717-26.
  28. Hollis BW, Wagner CL. Vitamin D and pregnancy: skeletal effects, nonskeletal effects, and birth outcomes. Calcif Tissue Int. 2013;92:128-39.
  29. Johner SA, von Nida K, Jahreis G, Remer T. [Time trends and seasonal variation of iodine content in German cow's milk--investigations from Northrhine-Westfalia]. Berl Munch Tierarztl Wochenschr. 2012;125:76-82.
  30. Kaiser L, Allen LH; American Dietetic Association. Position of the American Dietetic Association: nutrition and lifestyle for a healthy pregnancy outcome. J Am Diet Assoc 2008;108:553–61.
  31. Köhrle J, Petrides PE. Hypothalamisch-hypophysäres System und Zielgewebe. In: Löffler G, Petrides PE, Heinrich PC (Hrsg.). Biochemie und Pathobiochemie. 8. Auflage, Heidelberg, Springer; 2007, S. 841-892
  32. Koletzko B, Bauer CP, Bung P, Cremer M, Flothkötter M, Hellmers C, Kersting M, Krawinkel M, Przyrembel H, Rasenack R, Schäfer T, Vetter K, Wahn U, Weissenborn A, Wöckel A. German national consensus recommendations on nutrition and lifestyle in pregnancy by the 'healthy start - young family network'. Ann Nutr Metab. 2013;63:311-22. 
  33. Li Y, Shan Z, Teng W, Yu X, Li Y, Fan C, Teng X, Guo R, Wang H, Li J, Chen Y, Wang W, Chawinga M, Zhang L, Yang L, Zhao Y, Hua T. Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months. Clin Endocrinol (Oxf). 2010;72:825-9. 
  34. Liu NQ, Hewison M. Vitamin D, the placenta and pregnancy. Arch Biochem Biophys. 2012;523:37-47. 
  35. Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br J Nutr. 2012;108:1557-61.
  36. Luxwolda MF, Kuipers RS, Kema IP, van der Veer E, Dijck-Brouwer DA, Muskiet FA. Vitamin D status indicators in indigenous populations in East Africa. Eur J Nutr. 2013;52:1115-25. 
  37. Max Rubner-Institut Bundesforschungsinstitut für Ernährung und Lebensmittel. Nationale Verzehrsstudie II Ergebnisbericht, Teil 2. Die bundesweite Befragung zur Ernährung von Jugendlichen und Erwachsenen. Karslruhe, 2008. Online verfügbar unter: www.was-esse-ich.de/uploads/media/NVSII_Abschlussbericht_Teil_2.pdf
  38. Maxwell CS, Carbone ET, Wood RJ. Better newborn vitamin D status lowers RSV-associated bronchiolitis in infants. Nutr Rev. 2012;70:548-52. 
  39. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol. 2004;151 Suppl 3:U25-37.
  40. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662-87. 
  41. Obican SG, Jahnke GD, Soldin OP, Scialli AR. Teratology public affairs committee position paper: iodine deficiency in pregnancy. Birth Defects Res A Clin Mol Teratol. 2012;94:677-82.
  42. Pearce EN. Monitoring and effects of iodine deficiency in pregnancy: still an unsolved problem? Eur J Clin Nutr. 2013;67:481-4. 
  43. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12:976-89. 
  44. Principi N, Bianchini S, Baggi E, Esposito S. Implications of maternal vitamin D deficiency for the fetus, the neonate and the young infant. Eur J Nutr. 2013;52:859-67.
  45. Qian M, Wang D, Watkins WE, Gebski V, Yan YQ, Li M, Chen ZP. The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. Asia Pac J Clin Nutr. 2005;14:32-42. P
  46. Remer T, Johner SA, Gärtner R, Thamm M, Kriener E. [Iodine deficiency in infancy - a risk for cognitive development]. Dtsch Med Wochenschr. 2010;135:1551-6.
  47. Román GC, Ghassabian A, Bongers-Schokking JJ, Jaddoe VW, Hofman A, de Rijke YB, Verhulst FC, Tiemeier H. Association of gestational maternal hypothyroxinemia and increased autism risk. Ann Neurol. 2013;74:733-42.
  48. Román GC. Autism: transient in utero hypothyroxinemia related to maternal flavonoid ingestion during pregnancy and to other environmental antithyroid agents. J Neurol Sci. 2007;262:15-26.
  49. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-8. 
  50. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, Bischoff-Ferrari HA, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guérin AP, Heickendorff L, Hollis BW, Ish-Shalom S, Jean G, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev. 2010;9:709-15.
  51. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-125.
  52. Ströhle A, Wolters M, Hahn A. Nährstoffsupplemente ? Möglichkeiten und Grenzen. Teil 2: Ausgewählte Risikogruppen - Supplemente in der Schwangerschaft. Med Monatsschr Pharm. 2013;36:252-266 
  53. Ströhle A, Wolters M, Willer J, Hadji P, Hahn A. Mikronährstoffe in den verschiedenen Lebensphasen der Frau (Teil 3) ? Schwangerschaft: Nahrung für einen optimalen Start ins Leben. Gyne 2014 (im Druck)
  54. Ströhle A. Vitamin D – ein „archaischer“ Steroidabkömmling im Blickfeld der aktuellen Ernährungsforschung. Naturwiss Rdsch. 2011;64:173-180.
  55. Tabesh M, Salehi-Abargouei A, Tabesh M, Esmaillzadeh A. Maternal vitamin D status and risk of pre-eclampsia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98:3165-73.
  56. Wacker M, Holick MF. Vitamin D - effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5:111-48. 
  57. Wagner CL, Taylor SN, Dawodu A, Johnson DD, Hollis BW. Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. Nutrients. 2012;4:208-30.
  58. Wei SQ, Qi HP, Luo ZC, Fraser WD. Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2013;26:889-99. 
  59. World Health Organization, UNICEF, ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers. 3rd ed.: World Health Organization, 2007. Verfügbar unter: www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241595827/en/index.html.
  60. Wuertz C, Gilbert P, Baier W, Kunz C. Cross-sectional study of factors that influence the 25-hydroxyvitamin D status in pregnant women and in cord blood in Germany. Br J Nutr. 2013;110:1895-902. 
  61. Zhou SJ, Anderson AJ, Gibson RA, Makrides M. Effect of iodine supplementation in pregnancy on child development and other clinical outcomes: a systematic review of randomized controlled trials. Am J Clin Nutr. 2013;98:1241-54.
  62. Zimmermann MB. The role of iodine in human growth and development. Semin Cell Dev Biol. 2011;22:645-52.

Schlafstörungen in den Wechseljahren – pflanzliche Behandlungsalternativen zu Benzo & Co.

Specht, M. B.; Gerlach, A. Limbach, N. Pickartz, S.

 

  1. Ohayon MM. Epidemiological Overview of Sleep Disorders in the General Population. Sleep Med Res 2011; 2:1-9.
  2. Schlack R, Hapke U, Maske U, Busch M, Cohrs S. Frequency and distribution of sleep problems and insomnia in the adult population in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013; 56(5-6):740-8.
  3. Saletu B, Löffler H, Gruber D, Mandl M, Gruber G, Klösch G et al. Schlaflabor-untersuchungen zur Insomnie bei postmenopausalem Syndrom. J Menopause 1998; 4:29-36.
  4. Blümel JE, Cano A, Mezones-Holguín E, Barón G, Bencosme A, Benítez Z et al. A multinational study of sleep disorders during female mid-life. Maturitas 2012; 72(4):359-366.
  5. Soares CN, Murray BJ. Sleep Disorders in Women: Clinical Evidence and Treatment Strategies.  Psychiatr Clin North Am. 2006; 29(4):1095-1113.
  6. Thurston RC, Blumenthal JA, Babyak MA, Sherwood A. Association between hot flashes, sleep complaints, and psychological functioning among healthy menopausal women. Int J Behav Med 2006; 13(2):163-172.
  7. Sharkey KM, Bearpark HM, Acebo C, Millman RP, Cavallo A, Carskadon MA. Effects of menopausal status on sleep in midlife women. Behavioral sleep medicine 2003; 1(2):69-80.
  8. American Academy of Sleep Medicine: ICSD-2-International classification of sleep disorders, 2nd edn.: Diagnostic and coding manual. Westchester, USA, Illinois, 2005.
  9. Kaluza A, Hiller W, Specht MB, Volk S. Insomnieschwere – ein Vergleich zwischen zwei klinischen Stichproben unter Berücksichtigung zwanghafter Persönlichkeitszüge. Somnologie 2011; 15(Sonderheft 1):75.
  10. Estler C-J, Schmidt H, Hrsg. Pharmakologie und Toxikologie: für Studium und Praxis. 6. Auflage, Schattauer, Stuttgart New York, 2007.
  11. Mazza M, Losurdo A, Testani E, Marano G, Di Nicola M, Dittoni S et al. Polysomnographic findings in a cohort of chronic insomnia patients with benzodiazepine abuse. J Clin Sleep Med 2014; 10(1):35-42. doi:10.5664/jcsm.3354.
  12. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Phsychopharmacology 1997; 134(1):1-37.
  13. Roussin A, Bouyssi A, Pouché L, Pourcel L, Lapeyre-Mestre M. Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in France. PLoS One 2013;8(10):e76499. doi: 10.1371.
  14. Nordfjaern T, Bjerkeset O, Bratberg G, Moylan S, Berk M, Grawe R. Sociodemo-graphic, lifestyle and psychological  predictors of benzodiazepine and z-hypnotic use patterns. Nord J Psychiatry 2014; 68(2):107-116.
  15. Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schäfer-Korting M. Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie. 9. Auflage. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 2008.
  16. Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD: Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol 2011; 31:56-60.
  17. Proctor A, Bianchi MT. Clinical Pharmacology in Sleep Medicine. ISRN Pharmacol 2012; 914168. doi: 10.5402/2012/914168.
  18. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012; 2:e000850; doi:10.1136/bmjopen-2012-000850.
  19. Kommission E des ehemaligen Bundesgesundheitsamts. Monographie Valerianae radix, Baldrianwurzel. Bundesanzeiger, 13.3.1990.
  20. Kommission E des ehemaligen Bundesgesundheitsamts. Monographie Lupuli strobulus, Hopfenzapfen. Bundesanzeiger, 13.3.1990.
  21. Kommission E des ehemaligen Bundesgesundheitsamts. Monographie Melissae folium, Melissenblätter. Bundesanzeiger, 13.3.1990.
  22. Kommission E des ehemaligen Bundesgesundheitsamts. Monographie Baldrianwurzel, Hopfenzapfen und Melissenblätter, fixe Kombinationen. Bundesanzeiger, 8.5.1991.
  23. World Health Organization. Radix Valerianae. WHO monographs on selected medicinal plants. 1999, Vol. 1:267-276.
  24. World Health Organization. Strobilus Lupuli. WHO monographs on selected medicinal plants. 2007, Vol. 3: 236-246.
  25. World Health Organization. Melissae Folium. WHO monographs on selected medicinal plants. 2002, Vol. 2: 180-187.
  26. ESCOP Monographs. VALERIANAE RADIX – Valerian Root. European Scientific Cooperative on Phytotherapy, Second Edition 2003: 539-546.
  27. ESCOP Monographs. LUPULI FLOS – Hop Strobile. European Scientific Cooperative on Phytotherapy, Second Edition 2003: 306-311.
  28. ESCOP Monographs. MELISSAE FOLIUM – Melissa Leaf. European Scientific Cooperative on Phytotherapy, Second Edition 2003: 324-328.
  29. European Medicine Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Valeriana officinalis L., radix. EMEA/HMPC/340719/2005, 26 October 2006.
  30. European Medicine Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Humulus lupulus L., flos. EMEA/HMPC/513617/2006, 11 July 2008.
  31. European Medicine Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Melissa officinalis L, folium. EMA/HMPC/196745/2012, 14 May 2013.
  32. European Medicine Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos. EMA/HMPC/585558/2007, 6 May 2010.
  33. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC): Assessment Report on Valeriana officinalis L., radix. EMEA/HMPC/167391/2006, 29 November 2007.
  34. Herrera-Arellano A, Luna-Villegas G, Cuevas-Uriostegui ML, Alvarez L, Vargas-Pineda G, Zamilpa-Alvarez A et al. Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia. Planta Med 2001; 67(8): 695-699.
  35. Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause 2011; 18(9):951-955.
  36. Schultz H, Stolz C, Muller J. The effect of Valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiat 1994; 27(4):147-151.
  37. Schulz H, Jobert M. Die Darstellung sedierender/tranquilisierender Wirkungen von Phytopharmaka im quantifizierten EEG. Z Phytotherapie 6. Phytotherapie¬kongress, Berlin, 1995; Abstractband: 10.
  38. Nunes A, Sousa M. Use of valerian in anxiety and sleep disorders: what is the best evidence?. Acta Med Port 2011; 24(Suppl 4):961-966.
  39. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11(6):505-511.
  40. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia--a randomized, double-blind, comparative clinical study. Eur J Med Res. 2002; 7(11):480-486.
  41. Dorn M. Wirksamkeit und Verträglichkeit von Baldrian Versus Oxacepam bei nichtorganischen und nichtpsychiatrischen Insomnien: Eine randomisierte, doppelblinde klinische Vergleichsstudie. Forschende Komplementärmedizin und klassische Naturheilkunde. 2000;7:79–84.
  42. Zanoli P, Rivasi M, Zavatti M, Brusiani F, Baraldi M. New insight in the neuropharmacological activity of Humulus lupulus L. J Ethnopharmacol. 2005; 102(1):102-106.
  43. Zanoli P, Zavatti M, Rivasi M, Brusiani F, Losi G, Puia G et al. Evidence that the beta-acids fraction of hops reduces central GABAergic neurotransmission. J Ethnopharmacol. 2007; 109(1):87-92.
  44. Schiller H, Forster A, Vonhoff C, Hegger M, Biller A, Winterhoff H. Sedating effects of Humulus lupulus L. extracts. Phytomedicine 2006; 13(8):535-541.
  45. Negri G, di Santi D, Tabach R. Bitter acids from hydroethanolic extracts of Humulus lupulus L., Cannabaceae, used as anxiolytic.  Braz J Pharmacogn 2010; 20(6): 850-859.
  46. Koetter U, Schrader E, Käufeler R, Brattström A. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res 2007; 21(9): 847-851.
  47. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC): Assessment Report on Humulus lupulus L., flos. EMEA/HMPC/513618/2006, 11 July 2008.
  48. Wegener T. Phytopharmaka zur Anxiolyse – Zur Wirkung einer Kombination von Baldrian und Hopfen bei Angstzuständen. DAZ 2003; 143:618-25.
  49. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des 2006; 12(35):4613-4623.
  50. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC): Assessment Report on Melissa officinalis L., folium. EMA/HMPC/196746/2012, 14 May 2013.
  51. Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterr J Nutr Metab 2011; 4:211-218.
  52. Schellenberg R, Sauer S, Abourashed EA, Koetter U, Brattström A. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. Planta Med 2004; 70(7):594-597.
  53. Abourashed EA, Koetter U, Brattström A. In vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine 2004; 11:633-638.
  54. Butterweck V, Brattstroem A, Grundmann O, Koetter U. Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice. J Pharm Pharmacol 2007; 59(4):549-552.
  55. Cherniak, E. The use of alternative medicine for the treatment of insomnia in the elderly. Psychogeriatrics 2006; 6:21-30.
  56. Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005; 66(3):384-390.
  57. Meissner O, Häberlein H. Influence of xanthohumol on the binding behavior of GABAA receptors and their lateral mobility at hippocampal neurons. Planta Med 2006; 72:658-668.
  58. Salah SM, Jäger AK. Screening of traditionally used Lebanese herbs for neurological activities. J Ethnopharmacol 2005; 97(1):145-149.
  59. Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol 2007; 85(9):933-942.
  60. Yoo DY, Choi JH, Kim W, Yoo KY, Lee CH, Yoon YS et al. Effects of Melissa officinalis L. (lemon balm) extract on neurogenesis associated with serum corticosterone and GABA in the mouse dentate gyrus. Neurochem Res 2011; 36(2):250-7.
  61. Sadraei H, Ghannadi A, Malekshahi K. Relaxant effect of essential oil of Melissa officinalis and citral on rat ileum contractions. Fitoterapia 2003; 74(5):445-452.
  62. Friede M, Hasenfuß I, Wüstenberg P. Alltagssicherheit eines Phytosedativums aus Baldrianwurzeln, Hopfenzapfen und Melissenblättern. Nervenheilkunde 1999; 18:91-95.
  63. Volk S, Friede M, Hasenfuß I, Wüstenberg P. Phytosedativum gegen nervöse Unruhezustände und Einschlafstörungen. Zeitschrift für Phytotherapie 1999; 20:337-344
  64. Friede M. Pflanzliche Wirkstoffe gegen Schlafstörungen , T&E Neurologie Psychiatrie 1997; 11(10): 697-700.
  65. Friede M, Volk S, Laske A, Henneicke-von Zepelin HH: Is a phytosedative effective and safe in elderly patients? Results of a prospective cohort study. (2002). International Psychogeriatric Association. The Qualities of Aging, Rome, Italy, 2002.
  66. Specht MB, Spaude E, Kaluza A. Kurzintervention bei Insomnie, Kohlhammer, Stuttgart, 2014.
  67. Buysse, D. J., Germain, A., Moul, D. E., Franzen, P. L., Brar, L. K., Feltcher, M. E. et al. Efficacy of Brief Behavioral Treatment for Chronic Insomnia in Older Adults. Arch Intern Med 2011; 171(10):887-895.

Neue Zytologische Klassifikation – Münchner Nomenklatur III: Was ist wichtig für die Praxis?

Ulrich Schenck, Barbara Afheldt, Florian Bergauer, Thomas Weyerstahl

 

  1. Griesser, H., 2013, Münchner Nomenklatur III für die gynäkologische Zytodiagnostik der Zervix: Frauenarzt.
  2. Wagner, D., 1990, Münchner Nomenklatur II für die gynäkologische Zytodiagnostik.: Acta Cytol.,  34, p. 900–901.
  3. Qualitätssicherungsvereinbarung Zervix-Zytologie, 2007, Vereinbarung von Qualitätssicherungsmaßnahmen nach § 135 Abs. 2 SGB V zur zytologischen Untersuchung von Abstrichen der Cervix uteri (Qualitätssicherungsvereinbarung Zervix-Zytologie): Dt Aerztebl,  104,  p. A2446–A2451.
  4. Arbyn,M, A Anttila, J Jordan, G Ronco, U Schenck, N Segnan, H Wiener, A Herbert, J Daniel, von Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd Edition. 2008. European Communities, 2008. 
  5. Solomon, D. et al., 2002, The 2001 Bethesda System: terminology for reporting results of cervical cytology: JAMA,  287, p. 2114–2119.
  6. Herbert, A., C. Bergeron, H. Wiener, U. Schenck, P. Klinkhamer, J. Bulten, and M. Arbyn, 2007, European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology: Cytopathology, 18, p. 213–219.
  7. Soost, H. J., H. J. Lange, W. Lehmacher, and B. Ruffing-Kullmann, 1991, The validation of cervical cytology. Sensitivity, specificity and predictive values: Acta Cytol., 35, p. 8–14.
  8. Ciatto, S. et al., 1996, Interlaboratory reproducibility in reporting inadequate cervical smears--a multicentre multinational study: Cytopathology, 7, p. 386–390.
  9. Mitchell, H., and G. Medley, 1991, Longitudinal study of women with negative cervical smears according to endocervical status: Lancet, 337, p. 265–267.
  10. Greenspan, D. L., M. Cardillo, D. D. Davey, D. S. Heller, and A. T. Moriarty, 2006, Endometrial cells in cervical cytology: review of cytological features and clinical assessment: J.Low Genit.Tract.Dis., 10, p. 111–122.
  11. Simsir, A., W. Carter, P. Elgert, and J. Cangiarella, 2005, Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001: Am.J.Clin.Pathol., 123, p. 571–575.
  12. Blanks, R. G., and R. S. Kelly, 2010, Comparison of cytology and histology results in English cervical screening laboratories before and after liquid-based cytology conversion: do the data provide evidence for a single category of high-grade dyskaryosis?: Cytopathology,  21, p. 368–373.
  13. Blanks, R. G., 2010, Estimation of disease severity in the NHS cervical screening programme. Part II: quantitative methods of estimating disease severity and progression potential: Cytopathology.
  14. Herbert, A., 2004, BSCC terminology for cervical cytology: two or three tiers? Why not five, seven or even 14?: Cytopathology, 15, p. 245–251.
  15. Denton, K. J., A. Herbert, L. S. Turnbull, C. Waddell, M. S. Desai, D. N. Rana, N. Dudding, and J. H. Smith, 2008, The revised BSCC terminology for abnormal cervical cytology: Cytopathology,  19,  p. 137-157.
  16. Massad, L. S., M. H. Einstein, W. K. Huh, H. A. Katki, W. K. Kinney, M. Schiffman, D. Solomon, N. Wentzensen, and H. W. Lawson, 2013, 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors: Obstet.Gynecol., 121, p. 829–846.
  17. Carreon, J. D. et al., 2007, CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples: Int.J.Gynecol.Pathol., 26, p. 441–446.
  18. Jeronimo, J., M. J. Khan, M. Schiffman, and D. Solomon, 2005, Does the interval between papanicolaou tests influence the quality of cytology?: Cancer, 105, p. 133–138.

Hormonelle Neuroprotektion von beraterischem Interesse

J.M. Wenderlein  

 

  1. Behl Chr.: Estrogen - Mystery Drug for the Brain (Springerverlag 2001)
  2. Brizendine L.: Das weibliche Gehirn (Hoffmann und Campe 2007)
  3. Lautenbacher S.: Gehirn und Geschlecht (Springerverlag 2007)
  4. Riecher-Rössler A. et al: Psychische Störungen in Zeiten hormoneller Umstellung bei Frauen (Neuropsychiatrie 2006:20;155-185)
  5. Gärtner J. Östrogene im ZNS. Psychometrie . (Habilarbeit) Tübingen 2001
  6. Salis, B. Psychische Störungen im Wochenbett.. München: Elsevier Urban & Fischer. 2007
  7. O'Hara, M. W. (1995). Postpartum Depression. Causes and Consequences. New York: Springer-Verlag
  8. Gröhe, F. (2003) Nehmt es weg von mir. Depression nach der Geburt eines Kindes. Göttingen: Vandenhoeck & Ruprecht.
  9. Gregoire, A. (2005). Estrogens and Perinatal Disorders. In N. Bergemann & A. Riecher-Rössler (Hrsg.), Estrogens Effects in Psychiatric Disorders (S.191-207). Wien: Springer
  10. Riecher-Rössler, A. (2006). Was ist postpartale Depression. In B.Wimmer-Puchinger & A. Riecher-Rössler (Hrsg.), Postpartale Depression. Von der Forschung zur Praxis (S. 11-21). Wien: Springer.
  11. Gregoire, A. (2005). Estrogens and Perinatal Disorders. In N. Bergemann & A. Riecher-Rössler (Hrsg.), Estrogens Effects in Psychiatric Disorders (S. 191-207). Wien: Springer
  12. Sacher J1et al: Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an[11C]-harmine PET studyJ Psychiatry Neurosci. 2011 Nov;36(6):375-82. doi: 10.1503/jpn.100117.
  13. Kamel H et al:Risk of Thrombotic Event after the 6-Week Postpartum Period NEJM 2014 online 13.Feb;doi:1056/NEJMoa1311485
  14. Wenderlein J.M.: Aromatasehemmer riskant für das Gehirn? (Gebfra 2005:65;144-148)
  15. The Parkinson Study Group QE3Investigators A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease JAMA Neurol 2014,ePub24.3.2014.doi:10.1001/jamaneurol.2014;131
  16. Wenderlein M.et al:Antihormonelle Therpie bei Brustkrebs Frauenarzt 2013; 10. 990-993
  17. Lee RSet al: A meta-analysis of cognitive deficits in first-episode Major Depressive DisorderJournal of Affective Disorders [2012, 140(2):113-124]DOI: 10.1016/j.jad.2011.10.023
  18. Shao H et al:Hormone therapy and Alzheimer disease dementia:new findings from the Cache County Study Neurology.2012 ct 30;79 (18):1846-52
  19. Bull ain SS et al.Poor Physical Performance and Dementia in Oldest Old.The 90+Study JAMA Neurol 2013;70(1).107-113
  20. Wenderlein M.: Ein Drittel weniger Brustkrebs-Diagnosen unter HRT.Frauenarzt 52(2011)6:2-3

Personalisierte Therapie gynäkologischer Tumoren

Ruckhäberle E., Melcher C., Hagenbeck C., Fehm T.

 

  1. Krebs in Deutschland 2007/2008. 8. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2012
  2. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(suppl 7): vii11–vii19
  3. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24(9): 2206–23
  4. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Ann Surg Oncol. 2012 May; 19(5): 1508–16.
  5. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2011 Feb 1; 29(4): 456–63
  6. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 1; 28(1): 92–8
  7. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol. 2011 Jun; 22(6): 1308–17.
  8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011 61: 69–90.
  9. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009 9: 415–428.
  10. Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM; Sood AK, Stronach EA; Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 11: 719–725.
  11. Hsu CY, Bristow R, Cha MS, Wang BG, HO CL, Kurman RJ, Wang TL, Shih IeM. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004 10: 6432–6436.
  12. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011 474: 609–615.
  13. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26): 2484–96.
  14. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26): 2473–83.
  15. DuBois A, Floquet A, Kim JW, Rau J, Del Campo J M, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza M R, Monk B J, Wimberger P, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH., Kim J H, Harter P. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 31, 2013 (suppl; abstr LBA5503)